Molecular characteristics of renal cell carcinoma (RCC) risk groups from JAVELIN Renal 101.

Toni K. Choueiri,John B. A. G. Haanen,James Larkin,Brian I. Rini,Laurence Albiges,Robert J. Motzer,Alessandra di Pietro,Xinmeng Jasmine Mu,Keith A. Ching,Subramanian Hariharan,Paul B. Robbins

Molecular characteristics of renal cell carcinoma (RCC) risk groups from JAVELIN Renal 101.

2020

Toni K. Choueiri
John B. A. G. Haanen
James Larkin
Brian I. Rini
Laurence Albiges
Robert J. Motzer
Alessandra di Pietro
Xinmeng Jasmine Mu
Keith A. Ching
Subramanian Hariharan
Paul B. Robbins

744Background: The phase 3 JAVELIN Renal 101 trial in patients (pts) with advanced RCC demonstrated a progression-free survival (PFS) benefit and higher objective response rate (ORR) with avelumab ...

Keywords:

Avelumab
Oncology
Javelin
objective response
Pathology
Renal cell carcinoma
risk groups
Internal medicine
Medicine
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations